AGP Executive Report
Last update: 2 hours agoCancer Drug Update: The FDA granted accelerated approval to iberdomide (Zenbexus) for adults with relapsed or refractory multiple myeloma, in combination with daratumumab, hyaluronidase-fihj and dexamethasone—an oral option aimed at patients after at least one prior therapy line. Swiss Research & Care Access: Swissmedic is mentioned as part of the international Project Orbis review pathway, highlighting cross-border oncology regulation. Public Health & Safety: A Swiss sleep study report explains the “first-night effect,” where many people sleep less and wake more in unfamiliar places—an issue for travellers and shift workers. Medication & Patient Skills: A qualitative study on medication literacy after heart procedures points to gaps in how younger and middle-aged patients understand and manage post-PCI medicines. Policy Watch (Europe): France’s constitutional body upheld assisted-dying legislation, with safeguards—raising practical questions about palliative care access and oversight. Health Governance (Global): Cameroon President Paul Biya’s long absence, including time in Geneva, is renewing health-and-leadership concerns.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
